Lauren Bullaro Riker Sells 1,047 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX) VP Lauren Bullaro Riker sold 1,047 shares of Pacira BioSciences stock in a transaction that occurred on Friday, June 4th. The stock was sold at an average price of $61.04, for a total transaction of $63,908.88. Following the completion of the transaction, the vice president now directly owns 12,134 shares in the company, valued at approximately $740,659.36. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Lauren Bullaro Riker also recently made the following trade(s):

  • On Wednesday, March 17th, Lauren Bullaro Riker sold 2,000 shares of Pacira BioSciences stock. The stock was sold at an average price of $70.01, for a total transaction of $140,020.00.
  • On Monday, March 15th, Lauren Bullaro Riker sold 1,520 shares of Pacira BioSciences stock. The stock was sold at an average price of $73.28, for a total transaction of $111,385.60.

Shares of NASDAQ PCRX opened at $59.18 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.83 and a current ratio of 3.10. Pacira BioSciences, Inc. has a 12 month low of $40.96 and a 12 month high of $80.00. The company’s 50 day simple moving average is $63.90. The firm has a market cap of $2.61 billion, a PE ratio of 17.83 and a beta of 1.10.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings data on Monday, May 3rd. The company reported $0.53 EPS for the quarter, missing the consensus estimate of $0.64 by ($0.11). Pacira BioSciences had a net margin of 33.35% and a return on equity of 11.09%. The business had revenue of $119.00 million for the quarter, compared to analyst estimates of $119.23 million. During the same quarter in the previous year, the firm posted $0.53 earnings per share. The business’s revenue was up 12.6% on a year-over-year basis. Sell-side analysts forecast that Pacira BioSciences, Inc. will post 2.18 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in PCRX. The PNC Financial Services Group Inc. lifted its stake in shares of Pacira BioSciences by 23.6% in the 1st quarter. The PNC Financial Services Group Inc. now owns 19,682 shares of the company’s stock valued at $1,380,000 after purchasing an additional 3,759 shares during the period. Capital Insight Partners LLC acquired a new position in shares of Pacira BioSciences in the 1st quarter valued at $1,545,000. Teacher Retirement System of Texas acquired a new position in shares of Pacira BioSciences in the 4th quarter valued at $219,000. Swiss National Bank lifted its stake in shares of Pacira BioSciences by 1.2% in the 4th quarter. Swiss National Bank now owns 91,800 shares of the company’s stock valued at $5,493,000 after purchasing an additional 1,100 shares during the period. Finally, Rothschild Investment Corp IL lifted its stake in shares of Pacira BioSciences by 12.1% in the 1st quarter. Rothschild Investment Corp IL now owns 9,181 shares of the company’s stock valued at $643,000 after purchasing an additional 991 shares during the period.

PCRX has been the topic of a number of analyst reports. HC Wainwright lifted their price objective on shares of Pacira BioSciences from $70.00 to $86.00 and gave the stock a “buy” rating in a research report on Monday, March 1st. TheStreet cut shares of Pacira BioSciences from a “b” rating to a “c+” rating in a research note on Thursday, April 8th. BMO Capital Markets lowered their target price on shares of Pacira BioSciences from $72.00 to $70.00 and set a “market perform” rating for the company in a research note on Monday, May 10th. Northland Securities lowered their target price on shares of Pacira BioSciences from $75.00 to $66.00 and set a “market perform” rating for the company in a research note on Wednesday, May 5th. Finally, Berenberg Bank initiated coverage on shares of Pacira BioSciences in a research note on Friday, April 9th. They issued a “buy” rating and a $93.00 target price for the company. Four analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $77.54.

About Pacira BioSciences

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Further Reading: NASDAQ

Insider Buying and Selling by Quarter for Pacira BioSciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.